FORNARO, LUIGI
 Distribuzione geografica
Continente #
NA - Nord America 213
EU - Europa 104
AS - Asia 67
AF - Africa 8
Totale 392
Nazione #
US - Stati Uniti d'America 208
SG - Singapore 54
IT - Italia 46
DE - Germania 40
CI - Costa d'Avorio 8
IN - India 6
CA - Canada 5
CN - Cina 4
FI - Finlandia 4
NL - Olanda 4
FR - Francia 3
GB - Regno Unito 2
HK - Hong Kong 2
IE - Irlanda 2
BE - Belgio 1
GR - Grecia 1
JP - Giappone 1
RO - Romania 1
Totale 392
Città #
Chandler 47
Singapore 40
Ashburn 31
Seattle 15
Milan 14
Naples 14
Rome 7
Karlsruhe 5
Weng 5
Amsterdam 4
Pune 4
Santa Clara 4
Boston 3
Foggia 3
Freiburg im Breisgau 3
Lappeenranta 3
Lawrence 3
Los Angeles 3
Bhundsi 2
Council Bluffs 2
Dallas 2
Des Moines 2
Dublin 2
Esslingen am Neckar 2
Guangzhou 2
Houston 2
Kronberg 2
Millbury 2
Affing 1
Angri 1
Brussels 1
Germantown 1
Hachenburg 1
Helsinki 1
Kagoya 1
Krefeld 1
London 1
Montesarchio 1
Montreal 1
Ottawa 1
Paris 1
Rietheim-Weilheim 1
Schoenwalde 1
Union City 1
Vancouver 1
Totale 245
Nome #
Two is better than one: effectiveness of dupilumab on atopic dermatitis and chronic rhinosinusitis with nasal polyps in an adolescent 34
Herpes Zoster and Alopecia Areata following mRNA BNT162b2 COVID-19 vaccine: Controversial immune effects 28
Efficacy and Safety of Anti-TNF Biosimilars for Psoriasis in Pediatric and Geriatric Populations: A 72-Week Real-Life Study 26
Can COVID-19 cause atypical forms of pityriasis rosea refractory to conventional therapies? 26
Onset of vitiligo in a psoriasis patient on ixekizumab 25
A case of pediatric psoriasis successfully and rapidly treated with ixekizumab 23
The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review 21
Effects of COVID-19 pandemic on malignant melanoma diagnosis 21
Abrocitinib in atopic dermatitis: review of the current literature and clinical trials 18
Tattooing and hidradenitis suppurativa: stigmatization and camouflage 15
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data 15
Reply to 'Cutaneous adverse effects of the available COVID-19 vaccines in India: A questionnaire-based study' by Bawane J et al 15
A case of psoriasis and multiple sclerosis succesfully treated with concomitant fingolimod and secukinumab 14
New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge 13
The Use of JAK/STAT Inhibitors in Chronic Inflammatory Disorders 13
Generalized versus localized vitiligo after ixekizumab: May previous treatment affect the clinical presentation? 12
The impact of COVID-19 pandemic on nonmelanoma skin cancers: report of a Southern Italy referral centre 11
Step by step surgery for Hidradenitis Suppurativa 11
Reply to Borgia et al. Comment on “Marasca et al. Teledermatology and Inflammatory Skin Conditions during COVID-19 Era: New Perspectives and Applications. J. Clin. Med. 2022, 11, 1511” 10
Efficacy and safety of sonidegib for the management of basal cell carcinoma: a drug safety evaluation 9
How Adalimumab Impacts Antibiotic Prescriptions in Patients Affected by Hidradenitis Suppurativa: A 1-Year Prospective Study and Retrospective Analysis 8
Biologics for the Management of Erythrodermic Psoriasis: An Updated Review 8
Drug safety evaluation of ixekizumab for psoriasis: a review of the current knowledge 8
Efficacy and safety of spesolimab for the management of generalized pustular psoriasis: a drug safety evaluation 8
The Efficacy of Sonidegib in Treating Locally Advanced Basal Cell Carcinoma Involving the Periocular Area 8
Asymptomatic microscopic colitis induced by secukinumab 7
Management of Advanced Invasive Melanoma: New Strategies 6
Efficacy and Safety of Cemiplimab for the Management of Non-Melanoma Skin Cancer: A Drug Safety Evaluation 4
Totale 417
Categoria #
all - tutte 2.815
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.815


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202221 0 10 0 0 0 0 0 0 0 1 3 7
2022/2023142 4 1 7 19 32 19 1 13 16 7 11 12
2023/2024188 6 28 23 11 13 21 5 27 3 3 21 27
2024/202566 39 25 2 0 0 0 0 0 0 0 0 0
Totale 417